HER2阳性转移性乳腺癌患者对曲妥珠单抗皮下与静脉给药偏好:随机MetaspHer研究结果
可评估的意向治疗患者中,85.9%偏好皮下给药(P<0.001),安全性与该两种剂型已知特征一致。
要点
- 可评估的意向治疗患者中79/92(85.9%)偏好皮下曲妥珠单抗,13/92(14.1%)偏好静脉给药(P<0.001)。
- 医护人员对皮下给药满意度最高,56/88(63.6%,95%CI 53.6-73.7)表示最满意。
- 安全性人群中,皮下期73例(67.6%)、静脉期49例(44.1%)发生不良事件,安全性特征与已知一致。
核心结论
- 患者明确偏好皮下曲妥珠单抗,与早期乳腺癌PrefHer研究报告一致;安全性与该两种剂型的已知特征相符,未提出安全性担忧。
研究设计与样本
- 随机MetaspHer试验(NCT01810393),为首个在转移性乳腺癌中评估患者偏好的研究。
- 入组经一线化疗联合曲妥珠单抗后达到持续超过3年长期缓解的HER2阳性转移性乳腺癌患者。
- 随机接受3周期600 mg固定剂量皮下曲妥珠单抗(H-s.c.)后3周期标准静脉给药(H-i.v.),或相反顺序。
- 主要终点为第6周期时经患者偏好问卷(PPQ)评估的总体偏好;次要终点包括医护人员满意度、安全性与耐受性、生活质量。
主要发现
- 可评估意向治疗患者中,79/92(85.9%,95%CI 78.8-93.0,P<0.001)偏好皮下给药,13/92(14.1%,95%CI 7.0-21.3)偏好静脉给药。
- 医护人员对皮下给药最满意:56/88(63.6%,95%CI 53.6-73.7)。
- 安全性人群中,皮下给药期与静脉给药期分别有73例(67.6%)和49例(44.1%)发生不良事件。
- 皮下给药期与静脉给药期分别有7例(6.5%)和4例(3.6%)发生≥III级不良事件,3例(2.8%)和2例(1.8%)发生严重不良事件。
关键数值与推荐
- 主要终点为第6周期时经患者偏好问卷(PPQ)评估的总体偏好。
- 皮下给药为600 mg固定剂量,每3周期方案中先接受3周期皮下后3周期标准静脉给药,或相反顺序。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous (H-i.v.) and highly preferred by patients in early breast cancer. The present randomised MetaspHer trial (NCT01810393) is the first study assessing patient's preference in metastatic setting. METHODS: Patients with HER2-positive metastatic breast cancer who completed a first line chemotherapy with trastuzumab and achieved a long-term response lasting more than 3 years were randomised to receive 3 cycles of 600-mg fixed-dose adjuvant H-s.c., followed by 3 cycles of standard H-i.v., or the reverse sequence. Primary end-point was overall preference for H-s.c. or H-i.v. at cycle six, assessed by Patient Preference Questionnaire (PPQ). Secondary end-points included healthcare professional (HCP) satisfaction; safety and tolerability; quality of life. RESULTS: Hundred and thirteen patients were randomised and treated. H-s.c. was preferred by 79/92 evaluable intent-to-treat patients (85.9%, 95% confidence interval [CI; 78.8-93.0]; p < 0.001), 13/92 preferred H-i.v. (14.1%, 95% CI [7.0-21.3]). HCPs were most satisfied with H-s.c. (56/88 available data, 63.6%, [53.6-73.7]). On the safety population, adverse events occurred in 73 (67.6%) and 49 (44.1%) patients during the H-s.c. and H-i.v. periods, respectively; 7 (6.5%) and 4 (3.6%) were grade ≥ III, 3 (2.8%) and 2 (1.8%) were serious. CONCLUSION: The safety was consistent with the known H-i.v. and H-s.c. profiles without safety concern raised. Definitively, patients preferred H-s.c. as reported in early stage by PrefHer study.
引用
- Pivot X, Spano JP, Espie M, et al. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. Eur J Cancer. 2017. PMID: 28648618. doi:10.1016/j.ejca.2017.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。